Central testing
Clinical trials to collect data on the safety and efficacy of new medicinal products increasingly require specialised testing on top of safety assessment. What are the benefits of integrating specialised testing into central laboratory services? NGP asked James Chennells, Global Head of Strategic Sourcing Pharma Development Services for Bayer Healthcare Procurement, and Luc Leroy, CEO of Eurofins Medinet.
More >>

Omes and omics
Systems biology has had a huge impact on the drug discovery process. But do scientists agree on what this relatively new biological study field comprises? And what impact do the new capabilities in genomics and proteomics have on the pharmaceutical industry? NGP asked Gentronix’ Dr. Steve Beasley and Logopharm’s Uwe Schulte.
More >>

Tackling manufacturing challenges
By 2020, analysts predict, the pharmaceutical market will more than double to €829 billion ($1.3 trillion), with the E7 countries – Brazil, China, India, Indonesia, Mexico, Russia and Turkey – accounting around one fifth of global pharmaceutical sales. NGP looked at manufacturing units based in the north-east of England and asked Jacques Brom of sanofi aventis, Martin Inskip of Merck Sharp & Dohme Limited and Guy Wingateof GlaxoSmithKline how they are rising to the challenges of a globalised pharma industry.
More >>

Optimising sales force effectiveness
The ever-changing environment in which pharmaceutical companies promote their products has become increasingly tough over recent. The industry is under increasing pressure to deliver greater productivity from their sales forces. How do you recruit and continue to develop the highest quality sales management group in the industry? NGP asked Pierre De Nayer, Co-Founder and Managing Partner at Citobi, Andrej Hudoklin, Head of ’ Business Solutions Department, Chris Pepler, SVP of Global BD and Operations for Innovex, and Mike Poulson, President of Wilson Learning Europa.
More >>